🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the battle against drug-resistant strains of the infection, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with figures suggesting in excess of 82 million infections per year. Especially elevated rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, the spread of superbugs and the very limited available drugs currently available.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, marketed under the name a brand name, was authorized by the American regulatory agency in recent days for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone marks a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Data and Global Access

Based on results detailed in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which combines a dual-drug approach. The trial enrolled hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in many low-income and middle-income countries.

Medical professionals treating patients have shared positive views. Access to a single-dose, oral treatment of this kind is seen as a "revolutionary step" for managing the epidemic. This is viewed as essential to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea globally.